Evidence map›Paper›PMID 33635751›Full record

ReviewSeminars in ophthalmology2021

Single-cell RNA sequencing: An overview for the ophthalmologist.

Elizabeth J Rossin, Lucia Sobrin, Leo A Kim

Abstract readReview
In one paragraph

Review in Seminars in ophthalmology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Elizabeth J RossinMassachusetts Eye and Ear, Harvard Medical School Department of Ophthalmology, Boston, MA, USA.
Lucia SobrinMassachusetts Eye and Ear, Harvard Medical School Department of Ophthalmology, Boston, MA, USA.ORCID https://orcid.org/0000-0003-1575-0819
Leo A KimMassachusetts Eye and Ear, Harvard Medical School Department of Ophthalmology, Boston, MA, USA.

Funding

Role of Runx1 in Pathologic Ocular AngiogenesisR01EY027739 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI KIM, LEO A · 2018 to 2022
$2.8M
NEI NIH HHS R01 EY027739
6 · The paper itself

Abstract

Understanding the molecular composition of pathogenic tissues is a critical step in understanding the pathophysiology of disease and designing therapeutics. First described in 2009, single cell RNA sequencing (scRNAseq) is a methodology whereby thousands of cells are simultaneously isolated into individual micro-environments that can be altered experimentally and the genome-wide RNA expression of each cell is captured. It has undergone significant technological improvement over the last decade and gained tremendous popularity. scRNAseq is an improvement over prior pooled RNA analyses which cannot identify the cellular composition and heterogeneity of a tissue of interest. This new approach offers new opportunity for new discovery, as tissue samples can now be sub-categorized into groups of cell types based on genome-wide gene expression in an unbiased fashion. As ophthalmologists, we are uniquely positioned to obtain pathologic samples from the eye for further study. ScRNAseq has already been applied in ophthalmology to characterize retinal tissue, and it may offer the key to understanding various pathological processes in the future.

Indexed as

OphthalmologistsSequence Analysis, RNASingle-Cell AnalysisHumansgene expressionretinal pathologyretina surgeryRNA sequencingsingle cell

Identifiers

PMID33635751
PMCPMC9040911

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.